FENPIPRAMIDE is a parasympatholytic agent. As a hydrochloride salt, it is an active ingredient of some veterinary medicinal products used as analgesic drugs or antidotes. FENPIPRAMIDE was formerly used in humans as a spasmolytic in obstetrics.

Etanterol (VAL 481), a phenethanolamine derivative, is a β2 adrenoceptor agonist that was undergoing phase II trials in Italy as a bronchodilator with Valeas.

Pyrinoline is a substituted 2,3-dicarboximide patented by McNeil Laboratories, Inc. for the treatment of cardiac arrhythmias.

Setazindol is an anorectic.

Hexapradol was developed as a psychoanaleptic but was never marketed. Information about the current use of this drug is not available.

Cliropamine (D 16427) is a positive inotropic compound.

Talnetant (SB-223412) is a selective, orally active neurokinin 3 receptor antagonist and is under development for the potential treatment of several disorders, including irritable bowel syndrome, schizophrenia, chronic obstructive pulmonary disease, cough, overactive bladder and urinary incontinence. The most common adverse effects were headache, fatigue, and nausea.

Methaphenilene, an antihistaminic agent, was studied as a peroxisome proliferator. Information about the current use of this compound is not available.

Levonantradol is a synthetic cannabinoid analogue of delta (9)-tetrahydrocannabinol (delta(9)-THC) administered intramuscularly. It has antiemetic and anti-analgesic properties. Although its precise mechanism of action is unknown, levonantradol appears to bind and activate the cannabinoid receptors CB1 and/or CB2. Antiemetic effect of levonantradol significantly superior to chlorpromazine. However, its adverse central effects limit its utility. The main adverse events are drowsiness and dizziness. Levonantradol, administered intramuscularly to the patients suffering from postoperative pain, manifested significant analgesic efficacy. Analgesia persisted for more than 6 h with the 2.5 and 3 mg doses of levonantradol. Drowsiness was frequent but few other psychoactive effects were reported.

Atocalcitol is a vitamin D analogue. A hallmark of vitamin D3 analogues in psoriasis amelioration is the ability to inhibit the proliferation of keratinocytes. Atocalcitol had been in phase II clinical trials for the treatment of psoriasis. However, this research has been discontinued.